Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns Buy Rating from HC Wainwright

Lexicon Pharmaceuticals (NASDAQ:LXRXGet Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $4.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 344.44% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on the stock. Leerink Partnrs cut shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Wall Street Zen initiated coverage on shares of Lexicon Pharmaceuticals in a research note on Monday, April 21st. They issued a “sell” rating for the company. Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. Piper Sandler dropped their target price on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $1.00 price target (down from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $3.67.

Read Our Latest Stock Analysis on LXRX

Lexicon Pharmaceuticals Price Performance

LXRX opened at $0.90 on Tuesday. The company has a market capitalization of $325.34 million, a price-to-earnings ratio of -1.76 and a beta of 1.00. The company has a current ratio of 2.22, a quick ratio of 2.22 and a debt-to-equity ratio of 0.48. Lexicon Pharmaceuticals has a 12-month low of $0.28 and a 12-month high of $2.45. The business’s fifty day simple moving average is $0.67 and its 200-day simple moving average is $0.65.

Lexicon Pharmaceuticals (NASDAQ:LXRXGet Free Report) last released its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 568.04% and a negative return on equity of 103.16%. The company had revenue of $1.26 million during the quarter, compared to analyst estimates of $1.26 million. On average, equities research analysts anticipate that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC bought a new position in shares of Lexicon Pharmaceuticals during the 4th quarter worth approximately $38,000. Virtu Financial LLC purchased a new position in Lexicon Pharmaceuticals in the fourth quarter worth $66,000. Schonfeld Strategic Advisors LLC grew its holdings in Lexicon Pharmaceuticals by 301.5% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 7,558,621 shares of the biopharmaceutical company’s stock worth $5,582,000 after purchasing an additional 5,676,021 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in shares of Lexicon Pharmaceuticals during the fourth quarter worth $355,000. Finally, Deutsche Bank AG lifted its holdings in shares of Lexicon Pharmaceuticals by 378.0% during the 4th quarter. Deutsche Bank AG now owns 315,659 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 249,616 shares during the last quarter. 74.70% of the stock is currently owned by institutional investors.

About Lexicon Pharmaceuticals

(Get Free Report)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.

See Also

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.